Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study
Abstract Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its path...
Main Authors: | Nariman Moradi, Fatima Zahraa Fouani, Akram Vatannejad, Abbas Bakhti Arani, Soraya Shahrzad, Reza Fadaei |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | Lipids in Health and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12944-021-01514-9 |
Similar Items
-
Serum concentration of asprosin in new-onset type 2 diabetes
by: Shakiba Naiemian, et al.
Published: (2020-07-01) -
The impaired response of circulating asprosin concentrations to glucose levels fluctuation may be one of the causes of type 2 diabetes – a narrative review
by: Paulina Trojanowska, et al.
Published: (2020-09-01) -
Serum Asprosin Levels in Women with Polycystic Ovary Syndrome in Duhok City, Kurdistan Region of Iraq
by: Mohammed ameen, et al.
Published: (2021-06-01) -
The role of Asprosin in patients with dilated cardiomyopathy
by: Ming-Shien Wen, et al.
Published: (2020-09-01) -
Asprosin—A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature
by: Agnieszka Irena Mazur-Bialy
Published: (2021-02-01)